VistaGen Therapeutics analyst ratings
VistaGen Therapeutics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/22/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 05/20/2021 | 4916.72% | Baird | → $9 | Initiates Coverage On | → Outperform |
| 02/18/2021 | 3244.48% | Jefferies | → $6 | Initiates Coverage On | → Buy |
| 01/04/2021 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 10/08/2020 | 3244.48% | Aegis Capital | → $6 | Initiates Coverage On | → Buy |
| 08/28/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/22/2019 | 290.19% | Chardan Capital | $22 → $0.7 | Downgrades | Buy → Neutral |
| 06/27/2018 | 3244.48% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 05/24/2018 | 3244.48% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/22/2022 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 2021 年 5 月 20 日 | 4916.72% | 贝尔德 | → 9 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 2 月 18 日 | 3244.48% | 杰富瑞 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 01/04/2021 | — | 威廉布莱尔 | 升级 | 市场表现 → 跑赢大盘 | |
| 2020 年 8 月 10 日 | 3244.48% | 宙斯盾资本 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 08/28/2019 | — | 威廉布莱尔 | 启动覆盖范围开启 | → 跑赢大盘 | |
| 07/22/2019 | 290.19% | 查丹资本 | 22 美元 → 0.7 美元 | 降级 | 买入 → 中性 |
| 2018 年 6 月 27 日 | 3244.48% | Maxim 集团 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 05/24/2018 | 3244.48% | 奥本海默 | → 6 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
VistaGen Therapeutics Questions & Answers
VistaGen Therapeutics 问答
The latest price target for VistaGen Therapeutics (NASDAQ: VTGN) was reported by William Blair on July 22, 2022. The analyst firm set a price target for $0.00 expecting VTGN to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
威廉·布莱尔于2022年7月22日公布了VistaGen Therapeutics（纳斯达克股票代码：VTGN）的最新目标股价。该分析公司将目标股价定为0.00美元，预计VTGN将在12个月内跌至-100.00％（可能下跌-100.00％）。去年有1家分析公司公布了评级。
The latest analyst rating for VistaGen Therapeutics (NASDAQ: VTGN) was provided by William Blair, and VistaGen Therapeutics downgraded their market perform rating.
威廉·布莱尔提供了VistaGen Therapeutics（纳斯达克股票代码：VTGN）的最新分析师评级，VistaGen Therapeutics下调了其市场表现评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VistaGen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VistaGen Therapeutics was filed on July 22, 2022 so you should expect the next rating to be made available sometime around July 22, 2023.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与VistaGen Therapeutics的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。VistaGen Therapeutics的最后一次评级是在2022年7月22日提交的，因此你应该预计下一个评级将在2023年7月22日左右公布。
While ratings are subjective and will change, the latest VistaGen Therapeutics (VTGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price VistaGen Therapeutics (VTGN) is trading at is $0.18, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的VistaGen Therapeutics（VTGN）评级被下调，目标股价为0.00美元至0.00美元。VistaGen Therapeutics（VTGN）目前的交易价格为0.18美元，超出了分析师的预测区间。